Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Blood|August 12, 2009
Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behaviorFrancesco Forconi, Elisa Sozzi, Emanuele Cencini, et al.
Haematologica|November 8, 2011
CD20 expression has no prognostic role in Philadelphia-negative B-precursor acute lymphoblastic leukemia: new insights from the molecular study of minimal residual diseaseFrancesco Mannelli, Giacomo Gianfaldoni, Tamara Intermesoli, et al.
Blood|October 14, 2009
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemiaGianantonio Rosti, Francesca Palandri, Fausto Castagnetti, et al.
Blood Cancer Journal|November 14, 2020
Updated risk-oriented strategy for acute lymphoblastic leukemia in adult patients 18-65 years: NILG ALL 10/07Renato Bassan, Chiara Pavoni, Tamara Intermesoli, et al.
Haematologica|March 10, 2015
Randomized trial of radiation-free central nervous system prophylaxis comparing intrathecal triple therapy with liposomal cytarabine in acute lymphoblastic leukemiaRenato Bassan, Arianna Masciulli, Tamara Intermesoli, et al.
Blood|April 1, 2011
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working PartyGabriele Gugliotta, Fausto Castagnetti, Francesca Palandri, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 6, 2016
Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term OutcomeFederico Lussana, Tamara Intermesoli, Francesca Gianni, et al.
Blood|May 17, 2013
Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemiaDomenico Russo, Giovanni Martinelli, Michele Malagola, et al.
Blood|January 15, 2009
Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)Renato Bassan, Orietta Spinelli, Elena Oldani, et al.
Haematologica|April 7, 2022
Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 studyGabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, et al.
Pageof 5